GHRS
Gh Research Plc
NASDAQ · Pharmaceuticals
$15.17
+1.51 (+11.02%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 289.57M | 263.52M | 305.92M |
| Net Income | 46.13M | 45.80M | 47.46M |
| EPS | — | — | — |
| Profit Margin | 15.9% | 17.4% | 15.5% |
| Rev Growth | +11.0% | +19.2% | +2.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 203.88M | 161.25M | 163.65M |
| Total Equity | 299.85M | 295.49M | 320.57M |
| D/E Ratio | 0.68 | 0.55 | 0.51 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 85.32M | 72.54M | 88.44M |
| Free Cash Flow | 28.26M | 23.23M | 28.03M |